David Stefany
Boehringer Ingelheim
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David Stefany.
Bioorganic & Medicinal Chemistry Letters | 2009
Jiang-Ping Wu; Roman Wolfgang Fleck; Janice R. Brickwood; Alison Capolino; Katrina Mary Catron; Zhidong Chen; Charles L. Cywin; Jonathan Emeigh; Melissa Foerst; John David Ginn; Matt Hrapchak; Eugene R. Hickey; Ming-Hong Hao; Mohammed A. Kashem; Jun Li; Weimin Liu; Tina Marie Morwick; Richard M. Nelson; Daniel R. Marshall; Leslie Martin; Peter Allen Nemoto; Ian Potocki; Michel Liuzzi; Gregory W. Peet; Erika Scouten; David Stefany; Michael Robert Turner; Steve Weldon; Clare Zimmitti; Denise Spero
An SAR study that identified a series of thienopyridine-based potent IkappaB Kinase beta (IKKbeta) inhibitors is described. With focuses on the structural optimization at C4 and C6 of structure 1 (Fig. 1), the study reveals that small alkyl and certain aromatic groups are preferred at C4, whereas polar groups with proper orientation at C6 efficiently enhance compound potency. The most potent analogues inhibit IKKbeta with IC50s as low as 40 nM, suppress LPS-induced TNF-alpha production in vitro and in vivo, display good kinase selectivity profiles, and are active in a HeLa cell NF-kappaB reporter gene assay, demonstrating that they directly interfere with the NF-kappaB signaling pathway.
Bioorganic & Medicinal Chemistry Letters | 2013
Zhongli Gao; William J. Hurst; Werngard Czechtizky; Daniel Hall; Nicolas Moindrot; Raisa Nagorny; Philippe Pichat; David Stefany; James A. Hendrix; Pascal George
Lead optimization guided by histamine H3 receptor (H3R) affinity and calculated physico-chemical properties enabled simultaneous improvement in potency and PK properties leading to the identification of a potent, selective, devoid of hERG issues, orally bioavailable, and CNS penetrable H3R antagonist/inverse agonist 3h. The compound was active in forced-swimming tests suggesting its potential therapeutic utility as an anti-depressive agent. This Letter further includes its cardiovascular and neuropsychological/behavioral safety assessments.
Bioorganic & Medicinal Chemistry Letters | 2011
Lan Mu; Joacy C. Aguiar; Ali Ardati; Bin Cao; Charles J. Gardner; Tim Gillespy; Keith John Harris; Sungtaek Lim; Robert Marcus; Isabelle Morize; Ashfaq Parkar; David Stefany; Yi Li; Roy J. Vaz; Dragan A. Cirovic
A Comparative Molecular Similarity Indices Analysis (CoMSIA) was performed for 2,6-substituted-4-monosubstituted aminopyrimidine antagonists of prostaglandin D(2) receptor (DP). Both two-component (Q(2) = 0.63, R(2) = 0.82, SEE = 0.47 pIC(50)) and three-component (Q(2) = 0.70, R(2) = 0.91, SEE = 0.36 pIC(50)) CoMSIA models were established. Two hydrogen-bond acceptors with spatial separation of about 8Å are shown as optimal for binding. A large hydrophobic center that separates the two acceptors confers to the potency of the 2,6-substituted-4-monosubstituted aminopyrimidine. The models were used to predict IC(50) values for compounds which had functional groups different from those in the training set.
Archive | 2007
David Stefany; Keith John Harris; Timothy A. Gillespy; Charles J. Gardner; Joacy C. Aguiar
Archive | 2012
Zhongli Gao; Daniel Hall; David Stefany
Archive | 2011
Zhongli Gao; Daniel Hall; David Stefany
Archive | 2007
David Stefany; Keith John Harris; Timothy Allan Gillespy; Charles J. Gardner; Joacy C. Aguiar
Archive | 2007
David Stefany; Keith John Harris; Timothy A. Gillespy; Charles J. Gardner; Joacy C. Aguiar
Archive | 2006
Sungtaek Lim; Keith John Harris; David Stefany; Charles J. Gardner; Bin Cao; Ray Boffey; Timothy A. Gillespy; Joacy C. Aguiar; Hazle Joan Dyke; Elsa A. Dechaux
Archive | 2005
Sungtaek Lim; Keith John Harris; David Stefany; Charles J. Gardner; Bin Cao; Ray Boffey; Timothy A. Gillespy; Hazel J. Hunt; Elsa A. Dechaux; Joacy C. Aguiar